Triple-Hormone Drug Retatrutide Shows Record Weight Loss in Trial
A new obesity drug called retatrutide has demonstrated remarkable efficacy in a clinical trial, with participants losing up to 25% of their body weight. The drug works by simultaneously targeting three metabolic hormones: GLP-1, GIP, and glucagon. This triple-action approach appears to produce greater weight loss than existing treatments that typically target only one or two of these pathways. The trial results represent a significant advancement in pharmacotherapy for obesity, a condition affecting millions worldwide. Researchers noted that the drug's mechanism may also provide metabolic benefits beyond weight reduction, though further studies are needed to fully understand its long-term effects and safety profile.